Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update

Krystal Biotech, Inc. (NASDAQ:KRYS) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 3,370,000 shares, a decrease of 8.9% from the December 31st total of 3,700,000 shares. Based on an average daily trading volume, of 247,300 shares, the short-interest ratio is currently 13.6 days.

Krystal Biotech Trading Up 2.4 %

Shares of KRYS stock opened at $159.74 on Friday. The company has a 50 day simple moving average of $166.27 and a two-hundred day simple moving average of $180.01. The stock has a market cap of $4.59 billion, a P/E ratio of 90.25 and a beta of 0.85. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period last year, the firm earned ($0.67) EPS. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. As a group, equities analysts forecast that Krystal Biotech will post 3.03 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on KRYS shares. Chardan Capital restated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $206.67.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KRYS. State Street Corp lifted its holdings in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Geode Capital Management LLC raised its holdings in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after acquiring an additional 11,411 shares during the period. Franklin Resources Inc. lifted its position in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Krystal Biotech by 9.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock worth $43,727,000 after acquiring an additional 19,777 shares during the period. Finally, Braidwell LP raised its stake in Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).